PTHS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pelthos Therapeutics Inc (PTHS) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows potential for growth, supported by positive analyst ratings, a unique product in an underserved market, and improving financial metrics. While there are no immediate trading signals or congress trading data, the long-term outlook and market position make it a solid choice for this investor profile.
The MACD histogram is positive at 0.127, indicating bullish momentum, though it is contracting. RSI is neutral at 47.954, suggesting no overbought or oversold conditions. Moving averages are converging, indicating a potential trend change. The pre-market price of $26 is near the R1 resistance level of 26.16, showing potential for a breakout.
Analysts have given positive ratings with price targets ranging from $48 to $60, citing the potential of ZELSUVMI in an underserved market.
The company's lead product, ZELSUVMI, is the first home-use prescription therapy for Molluscum contagiosum, offering a unique market advantage.
Financial metrics show significant improvement, with net income up 858.19% YoY and EPS up 80.89% YoY.
The Q4 TRx count for ZELSUVMI fell below expectations, which could indicate slower-than-expected adoption.
The company operates at a net loss, and while cash reserves are sufficient for now, they may require additional funding by Q4 2026.
In Q3 2025, revenue remained flat YoY at $7.406M. However, net income improved significantly, reducing losses by 858.19% YoY. EPS also improved by 80.89% YoY, and gross margin remained stable at 59.56%. These metrics indicate improving financial health despite ongoing losses.
Analysts are optimistic about PTHS, with Piper Sandler initiating coverage with an Overweight rating and a $48 price target, Roth Capital maintaining a Buy rating with a $55 price target, and Oppenheimer raising its price target to $60. Analysts highlight the potential of ZELSUVMI and the company's long-term growth prospects.
